TY - JOUR
T1 - High prevalence of advanced colorectal neoplasia and serrated polyposis syndrome in Hodgkin lymphoma survivors
AU - Rigter, Lisanne S.
AU - Spaander, Manon C.W.
AU - Aleman, Berthe M.P.
AU - Bisseling, Tanya M.
AU - Moons, Leon M.
AU - Cats, Annemieke
AU - Lugtenburg, Pieternella J.
AU - Janus, Cecile P.M.
AU - Petersen, Eefke J.
AU - Roesink, Judith M.
AU - van der Maazen, Richard W.M.
AU - Snaebjornsson, Petur
AU - Kuipers, Ernst J.
AU - Bruno, Marco J.
AU - Dekker, Evelien
AU - Meijer, Gerrit A.
AU - de Boer, Jan Paul
AU - van Leeuwen, Flora E.
AU - van Leerdam, Monique E.
N1 - Publisher Copyright:
© 2018 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society
PY - 2019/3/15
Y1 - 2019/3/15
N2 - Background: Hodgkin lymphoma (HL) survivors treated with abdominal radiotherapy and/or alkylating chemotherapy have an increased risk of colorectal cancer (CRC). This study was aimed at evaluating the prevalence of colorectal neoplasia in HL survivors. Methods: This multicenter cohort study assessed the diagnostic yield of advanced colorectal neoplasia detected by a first surveillance colonoscopy among HL survivors treated with abdominal radiotherapy and/or procarbazine. Advanced colorectal neoplasia included advanced adenomas (high-grade dysplasia, ≥25% villous component, or ≥10-mm diameter), advanced serrated lesions (dysplasia or ≥10-mm diameter), and CRC. The results were compared with those for a Dutch general population cohort that underwent a primary screening colonoscopy (1426 asymptomatic individuals 50-75 years old). This study demonstrated the results of a predefined interim analysis. Results: A colonoscopy was performed in 101 HL survivors, who were significantly younger (median, 51 years; interquartile range [IQR], 45-57 years) than the general population controls (median, 60 years; IQR, 55-65 years; P <.001). The prevalence of advanced neoplasia was higher in HL survivors than controls (25 of 101 [25%] vs 171 of 1426 [12%]; P <.001). Advanced adenomas were detected in 14 of 101 HL survivors (14%) and in 124 of 1426 controls (9%; P =.08). The prevalence of advanced serrated lesions was higher in HL survivors than controls (12 of 101 [12%] vs 55 of 1426 [4%]; P <.001). Serrated polyposis syndrome was present in 6% of HL survivors and absent in controls (P <.001). Conclusions: HL survivors treated with abdominal radiotherapy and/or procarbazine have a high prevalence of advanced colorectal neoplasia. The implementation of a colonoscopy surveillance program should be considered.
AB - Background: Hodgkin lymphoma (HL) survivors treated with abdominal radiotherapy and/or alkylating chemotherapy have an increased risk of colorectal cancer (CRC). This study was aimed at evaluating the prevalence of colorectal neoplasia in HL survivors. Methods: This multicenter cohort study assessed the diagnostic yield of advanced colorectal neoplasia detected by a first surveillance colonoscopy among HL survivors treated with abdominal radiotherapy and/or procarbazine. Advanced colorectal neoplasia included advanced adenomas (high-grade dysplasia, ≥25% villous component, or ≥10-mm diameter), advanced serrated lesions (dysplasia or ≥10-mm diameter), and CRC. The results were compared with those for a Dutch general population cohort that underwent a primary screening colonoscopy (1426 asymptomatic individuals 50-75 years old). This study demonstrated the results of a predefined interim analysis. Results: A colonoscopy was performed in 101 HL survivors, who were significantly younger (median, 51 years; interquartile range [IQR], 45-57 years) than the general population controls (median, 60 years; IQR, 55-65 years; P <.001). The prevalence of advanced neoplasia was higher in HL survivors than controls (25 of 101 [25%] vs 171 of 1426 [12%]; P <.001). Advanced adenomas were detected in 14 of 101 HL survivors (14%) and in 124 of 1426 controls (9%; P =.08). The prevalence of advanced serrated lesions was higher in HL survivors than controls (12 of 101 [12%] vs 55 of 1426 [4%]; P <.001). Serrated polyposis syndrome was present in 6% of HL survivors and absent in controls (P <.001). Conclusions: HL survivors treated with abdominal radiotherapy and/or procarbazine have a high prevalence of advanced colorectal neoplasia. The implementation of a colonoscopy surveillance program should be considered.
KW - colorectal cancer (CRC) screening
KW - epidemiology
KW - polyps/adenomas
UR - http://www.scopus.com/inward/record.url?scp=85058695006&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85058695006&partnerID=8YFLogxK
U2 - 10.1002/cncr.31903
DO - 10.1002/cncr.31903
M3 - Article
C2 - 30561773
AN - SCOPUS:85058695006
SN - 0008-543X
VL - 125
SP - 990
EP - 999
JO - Cancer
JF - Cancer
IS - 6
ER -